newsfilter
← Latest News
Business Wire·

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

- Phase 1b study for the potential treatment of osteoarthritis and low back pain expected to commence in the first quarter of 2025 - Initial data readout planned for early 2026 - Neuropathic component of chronic pain